Want to see JP:4549 full AI Analyst Report?
4549 Stock Chart & Stats
¥2580.00
-¥78.00(-3.07%)
At close: 4:00 PM EDT
¥2580.00
-¥78.00(-3.07%)
Day’s Range― - ―
52-Week Range¥2,021.00 - ¥3,500.00
Previous CloseN/A
Volume357.70K
Average Volume (3M)163.76K
Market Cap
¥74.11B
Enterprise Value¥79.97B
Total Cash (Recent Filing)¥9.89B
Total Debt (Recent Filing)¥5.88B
Price to Earnings (P/E)20.9
Beta0.56
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.57%
Share Statistics
EPS (TTM)107.82
Shares Outstanding34,541,440
10 Day Avg. Volume76,470
30 Day Avg. Volume163,760
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)2.29
Price to Sales (P/S)2.40
P/FCF Ratio-58.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.9
Revenue Forecast (FY)¥43.56B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and substantial equity provide a durable financial cushion, reducing balance-sheet pressure while preserving flexibility to invest in diagnostic products, systems, and market expansion. This supports resilience if operating conditions remain uneven over the next several quarters.
Recurring Reagent Revenue ModelThe reagent-led model can support repeat purchasing because consumables are used continuously in routine clinical testing. Revenue linked to installed customer workflows and test volumes may provide greater durability than relying only on occasional instrument sales.
Specialized Diagnostics PositioningA focused position in in vitro diagnostics connects the company with essential disease detection and health-screening activities. Its combination of reagents and supporting systems can deepen relevance to laboratories and create a specialized platform for ongoing product development.
Bears Say
Negative Free Cash FlowThe shift to negative free cash flow indicates that earnings are no longer translating into internally generated cash as reliably as before. This can constrain funding for product development, investment, and shareholder returns unless cash conversion improves over coming quarters.
Material Margin CompressionThe sustained deterioration from earlier gross and operating margin levels signals reduced earnings power, potentially reflecting weaker pricing, product mix, or cost pressure. Lower margins leave less operating cushion and make profitability more sensitive to changes in revenue or expenses.
Weak Revenue RecoveryThe sharp revenue setback followed by only modest recovery suggests that top-line momentum remains limited relative to the company’s earlier trajectory. Slower growth can restrict operating leverage, reduce investment capacity, and make margin recovery harder to achieve.
Eiken Chemical Co., Ltd. News
4549 FAQ
What was Eiken Chemical Co., Ltd.’s price range in the past 12 months?
Eiken Chemical Co., Ltd. lowest stock price was ¥2021.00 and its highest was ¥3500.00 in the past 12 months.
What is Eiken Chemical Co., Ltd.’s market cap?
Eiken Chemical Co., Ltd.’s market cap is ¥74.11B.
When is Eiken Chemical Co., Ltd.’s upcoming earnings report date?
Eiken Chemical Co., Ltd.’s upcoming earnings report date is Oct 29, 2026 which is in 23 days.
How were Eiken Chemical Co., Ltd.’s earnings last quarter?
Eiken Chemical Co., Ltd. released its earnings results on Jul 30, 2026. The company reported ¥13.52 earnings per share for the quarter.
Is Eiken Chemical Co., Ltd. overvalued?
According to Wall Street analysts Eiken Chemical Co., Ltd.’s price is currently Overvalued.
Does Eiken Chemical Co., Ltd. pay dividends?
Eiken Chemical Co., Ltd. pays a Semiannually dividend of ¥29 which represents an annual dividend yield of 2.57%. See more information on Eiken Chemical Co., Ltd. dividends here
What is Eiken Chemical Co., Ltd.’s EPS estimate?
Eiken Chemical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eiken Chemical Co., Ltd. have?
Eiken Chemical Co., Ltd. has 34,541,440 shares outstanding.
What happened to Eiken Chemical Co., Ltd.’s price movement after its last earnings report?
Eiken Chemical Co., Ltd. reported an EPS of ¥13.52 in its last earnings report. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Eiken Chemical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4549
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eiken Chemical Co., Ltd.
Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.
Technical Analysis
PHC Holdings Corp.
―
Techno Medica Co., Ltd.
―
Rion Co., Ltd.
―
Nihon Kohden Corporation
―